tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascendis Pharma price target raised to $290 from $243 at Citi

Citi raised the firm’s price target on Ascendis Pharma (ASND) to $290 from $243 and keeps a Buy rating on the shares post the Q2 report. The firm says Yorvipath posted strong sales and is on its way to becoming a blockbuster.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1